Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
The effects of empagliflozin treatment on hepatocellular lipid content, liver energy
metabolism and body composition will be investigated in a multicentre, prospective,
placebo-controlled, double-blind, randomized, 2-arm parallel, interventional and exploratory
pilot study in patients with newly diagnosed type 2 diabetes.